Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Portola Pharmaceuticals Inc    PTLA

PORTOLA PHARMACEUTICALS INC (PTLA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
39.21(c) 40.04(c) 40.24(c) 40.28(c) 40.1(c) Last
472 136 556 096 495 948 1 263 571 482 884 Volume
-0.28% +2.12% +0.50% +0.10% -0.45% Change
More quotes
Financials (USD)
Sales 2018 58,1 M
EBIT 2018 -355 M
Net income 2018 -354 M
Finance 2018 27,6 M
Yield 2018 -
Sales 2019 321 M
EBIT 2019 -121 M
Net income 2019 -133 M
Debt 2019 192 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 44,9x
EV / Sales2019 8,83x
Capitalization 2 640 M
More Financials
Company
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation.Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation... 
More about the company
Surperformance© ratings of Portola Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PORTOLA PHARMACEUTICALS IN
07/09PORTOLA PHARMACEUTICALS : Reports Inducement Grants under NASDAQ Listing Rule 56..
AQ
07/04PORTOLA PHARMACEUTICALS : Reports Inducement Grants Under NASDAQ Listing Rule 56..
AQ
07/03Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5..
GL
06/28PORTOLA PHARMACEUTICALS : Appoints 30-Year Industry Veteran Glenn Brame as Senio..
AQ
06/26PORTOLA PHARMACEUTICALS : Appoints 30-Year Industry Veteran Glenn Brame as Senio..
AQ
06/25Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Seni..
GL
06/19PORTOLA PHARMACEUTICALS INC : Today's Research Reports on Trending Tickers: Port..
AC
06/11PORTOLA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Amendme..
AQ
06/06PORTOLA PHARMACEUTICALS : to Present at Two Upcoming Investor Conferences
AQ
06/06PORTOLA PHARMACEUTICALS : has 3 `differentiated assets` with strong potential, s..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/17Zacks: Analysts Expect Portola Pharmaceuticals Inc $PTLA Will Post Earnings o.. 
07/12Brokerages Expect Portola Pharmaceuticals Inc $PTLA Will Announce Earnings of.. 
07/10Get the latest ratings for $RCPT $ECOM $XGTI $CMFN $PTLA in your inbox with M.. 
07/03Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5.. 
06/30Portola Pharmaceuticals $PTLA Stock Rating Lowered by ValuEngine  
More tweets
Qtime:68
News from SeekingAlpha
07/17Playing The Expectations Game In Biotech 
06/19The Market Needs A Glum Index - Cramer's Mad Money (6/18/18) 
06/07CORE BIOTECH BUYS #18 : Thoughts On ASCO And The End Of Core Biotech 
06/04Portola Pharma CEO Lis to retire; shares -2% 
06/01PORTOLA PHARMACEUTICALS : Compelling Buyout Target 
Chart PORTOLA PHARMACEUTICALS IN
Duration : Period :
Portola Pharmaceuticals In Technical Analysis Chart | PTLA | US7370101088 | 4-Traders
Technical analysis trends PORTOLA PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 60,5 $
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
William Lis Chief Executive Officer & Director
Mardi C. Dier Co-President, Chief Financial Officer & EVP
John T. Curnutte Co-President, EVP-Research & Development
Hollings Chase Renton Chairman
W. Richey Neuman Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PORTOLA PHARMACEUTICALS INC-17.63%2 640
CELLTRION, INC.--.--%32 792
IQVIA HOLDINGS INC11.34%22 131
LONZA GROUP9.38%21 576
INCYTE CORPORATION-25.97%14 878
SEATTLE GENETICS, INC.28.95%11 147